Clarity Pharmaceuticals Rises 7% Amid Promising Trial Results and New Supply Agreement

March 05, 2025 11:06 AM AEDT | By Team Kalkine Media

Clarity Pharmaceuticals Rises 7% Amid Promising Trial Results and New Supply Agreement — Image source: Shutterstock

Breakthrough in SECuRE Trial

The first announcement detailed the progress of Clarity’s SECuRE trial, a Phase I/IIa theranostic study targeting patients with prostate-specific membrane antigen (PSMA)-expressing metastatic castration-resistant prostate cancer (mCRPC). The trial uses 64Cu-SAR-bisPSMA to visualize PSMA-expressing lesions, helping to identify suitable candidates for treatment with 67Cu-SAR-bisPSMA therapy.

According to the company’s statement, the Dose Escalation Phase of the trial has been successfully completed. Based on robust safety and efficacy data, the Safety Review Committee (SRC) has given the green light to progress to the Cohort Expansion Phase (Phase II) at the 8 GBq dose level of 67Cu-SAR-bisPSMA. This milestone marks a significant step forward in Clarity’s mission to provide innovative, targeted therapies for prostate cancer patients.

Strengthening Research with a New Supply Agreement

In addition to the trial progress, Clarity announced a new supply agreement with The University of Queensland’s advanced imaging facility at the Australian Institute for Bioengineering and Nanotechnology (AIBN). The agreement ensures a reliable supply of copper-64 (64Cu) isotopes, a critical component for the company’s imaging and diagnostic technologies.

This partnership not only supports the continued development of the 64Cu-SAR-bisPSMA imaging agent but also paves the way for future research. The supply will aid the advancement of two pre-clinical theranostic programs — 64/67Cu-SAR-bisFAP and 64/67Cu-SAR-trastuzumab — potentially expanding Clarity’s portfolio of innovative cancer treatments.

Investor Optimism and Future Prospects

With two positive announcements in one day, investor sentiment has surged, reflecting confidence in Clarity's strategic direction. The combination of clinical success and strengthened research capabilities positions the biotech company as a rising star in the field of targeted cancer diagnostics and therapeutics.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.